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OBJECTIVES
Evaluate the correlation between peak oxygen consumption 
(VO2peak), from cardiopulmonary test with the distance covered 
in the six-minute walk test (6MWT) in healthy elderly and 
with myocardial infarction (MI).
METHODS
Thirty individuals were studied, with age range 65 – 87 
years (76, 03± 4,75),  divided into 2 groups: Group I – 14 
with clinically evident coronary heart disease (CHD) and 
Group II – 16 without clinically evident CHD. They were 
submitted to cardiopulmonary test (CPT) and 2 types of 
6MWT, standard test 6MWTs.  Variables measure at rest 
and exertion were heart rate (HR) and respiratory rate (RR), 
blood pressure (BP), distance covered (DC), and Borg’s rate 
subjective perceived exertion (RPE).
RESULTS
The study showed signifi cant, strong correlation between 
distances covered for both 6MWT, and (VO2peak) obtained 
from cardiopulmonary test (CPT) for all elderly included in 
the study. When comparing the 6MWT with physiotherapist 
support (6MWTphy) and without support (6MWTw), 
statistically signifi cant difference was observed, with higher 
average values of the DC, of the RH and RR and Borg’s RPE 
in the 6MWTphy, both of the groups. Addtionally,  the RH 
reached at fi nal the exertion in 6MWTphy was similar to 
that obtained in CPT (p<0,05) suggesting that the 6MWT 
stimulates higher cardiovascular performance. 
CONCLUSION
6MWTw, adopted a worldwide, by being submaximal 
imposes lower cardiovascular overburden as compared 
to 6MWTphy and is probably safer for elderly who are 
cardiopaths. 
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Functional ability analysis through cardiopulmonary 
test (CPT) is widely used for prognostic and therapeutic 
evaluation of patients with congestive heart failure (CHF) 
1-6. However, its applicability poses restriction to elderly 
without and with cardiopathy, due to high cost, associated 
to ageing process inherent limitations7,8.
The 6-minute walk test (6MWT) is a low cost, better 
tolerated choice option, in addition to allowing patients 
to determine the speed and the need for pauses, which 
stands as an additonal advantage for the elderly9,8,10-12. 
The submaximal13,11 6MWT is the renowned worldwide; 
however, there is a linear correlation between total 
distance covered and peak oxygen consumption (VO2peak) 
obtained through cardiopulmonary test14,15,9. 
Most protocols use verbal stimulus, when signifi cant 
increase of distance covered12 can be observed.
Other authors, however, have shown that the pattern 
using 6MWT with support by examiner side by side with 
patient, giving pace to their walk in addition to verbal 
stimulus, improves test performance, which is shown by 
the distance covered when compared to 6MWT with no 
physiotherapist in normal individuals and in patients with 
chronic obstructive pulmonary disease.16
The primary objective in the present study was 
to evaluate the correlation between peak oxygen 
consumption obtained from cardiopulmonary test, and 
the distance covered in the 6-minute walk test in healthy 
elderly with myocardial infarction (MI). Secondly, compare 
walk test performance with and without monitoring.
METHODS
This is a cross-sectional, observational study, to 
investigate 98 individuals who are 65 years old or 
older: 72 were post myocardial infarction patients, 
and 26 were elderly patients with no clinically evident 
cardiopathy. From those, sixty-eight (68) patients 
were not eligible, due to orthopedic pathologies and/or 
balance disorders (n = 55), or chronic pulmonary 
obstructive disease (COPD) (n = 13). Thirty (30) 
individuals who fulfi lled inclusion criteria were selected 
consecutively. Patients’ age ranged from 65 to 87 years 
of age, with mean at 76.03 ± 4.75. From the total, 
18 elderly (60%) were females, and 12 (40%), males. 
The elderly were prospectively divided into 2 groups: 
Group I – made up of 14 elderly patients (8 females 
and 6 males), with confi rmed myocardial infarction, 
on β-blockers, clinically stable, which means to say, 
with no signs or symptoms of heart failure or unstable 
angina, with mean age 76.4 ± 5.07 years (age range 
65-85 years old), from the Cardiogeriatrics Outpatient 
Unit, Department of Cardiology, at the São Paulo 
Federal University (UNIFESP); and Group II – made up 
of 16 elderly patients (10 females and 6 males), with 
mean age 75.6 ± 4.58 years (age range 66-87 years 
old),with no clinically evident CHD at clinical exam, and 
electrocardiogram at baseline and on exertion, screened 
from the EPIDOSO Study (Epidemiology of the Elderly 
– Epidemiologia do Idoso), a longitudinal study, with 
a population of elderly patients (age ≥ 65 ), all São 
Paulo residents, after a regional census study carried 
out by the Ageing Study Center (Centro de Estudos do 
Envelhecimento) at the same institution. The study was 
approved by the Ethics Committee at the University 
hospital it was carried out. All participants signed 
the informed consent. Patients were examined and 
screened by a physician at the Cardiogeriatrics Service. 
Clinical examination included a detailed questionnaire 
of diagnoses, risk factors and conditions associated, 
medications being used, clinical exam and ECG. The 
groups showed to be homogeneous in regard to clinical 
and demographical characteristics (Table 1). The 
characteristics shown by the group of infarcted patients 
on β-blockers can be found in Table 2. 
Table 1 – Clinical and demographic group data: age, gender, risk factors and number of risk factors
Variables Total Group 1 Group 2 p
n = 30 n = 14 n = 16
Age (mean)
76.03 ± 4.75 75.6 ± 4.58 76.4 ± 5.07 0.680
Gender (n, %)
 Male 12 (40%) 06 (42.86%) 06 (37.5%) 0.765
 Females 18 (60%) 08 (57.14%) 10 (62.5%) 
Risk factors (n, %)
 Hypertension 14 (46.6%) 10 (71.43%) 04 (25.0%) 0.014
 Diabetes Mellitus 04 (13.3%) 03 (21.42%) 01 (6.25%) 0.249
 Dyslipidemia 23 (76.6%) 10 (71.43%) 13 (81.25%) 0.574
 Currently smoking 02 (6.60%) 01 (7.14%) 01 (6.25%) 0.724
 Sedentariness 11 (36.67%) 05 (35.71%) 06 (37.5%) 0.919
 BMI > 27 (kg/m²) 12 (40.00%) 06 (42.86%) 06 (37.5%) 0.765
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Tests were carried out in a climatized laboratory, with 
temperature ranging from18° to 22 °C, and humidity 
between 40 and 60%, in compliance with II Guidelines 
on ergonometric test by the Brazilian Society of Cardiology 
(2002)17 and the National Ergonometry Consensus 
(1995)18. 
In both groups, the protocol by Weber and 
collaborators19 was applied on the ergometric treadmill 
(Precor C964i-USA). Twelve-lead electrocardiographic 
records (ECG) were taken at rest and in supine position, 
and in modifi ed 3-lead ECG positions - CM5, VF and 
V2 – as well as in orthostic position. During the test, 
through the use of computerized Ergo-S, Dixtal-Brasil 
and automatic recording of HR and ECG line at the 
end of each stage every 2 minutes during the course 
of test up to exhaustion, ending with recording every 
minute in the three recovery phases was carried out. In 
combination, peak oxygen consumption was obtained by 
a low pressure valve (Hans Rudolf-USA), connected to 
oxygen (O2) and carbonic gas (CO2) analyzers - Ametek-
USA, O2 Analyser S- 3A/L and CO2 Analyser CD- 3
A, 
interconnected to the Vacumed-Vista Turbofi t system 
- Version 320-USA, with acquisitions every 30 seconds 
from resting position.
The 6-minute walk test (6MWT) was carried out on 
fl at fl oor, being 25 meters on straight line, and always 
applied by the same examiner two or three days following 
cardiopulmonary test.
After being acquainted with the test, patients 
were submitted to two standard techniques. The fi rst 
one applied the 6MWT according to the American 
Association of Cardiovascular & Pulmonar Rehabilitation 
(ACVPR)20, and the Guidelines for Six-Minute Walk Test 
(6MWT) by the ATS21, with verbal stimulation every 30 
seconds. The second standard technique conducted the 
6MWT with monitoring, as described by Cavalheiro et 
al16, when the examiner would walk along, lead the 
pace and verbally stimulate patients every minute with 
incentive tag lines (“you’re doing great”, “walk as fast 
as you can”).
Heart rate and respiratory rate, blood pressure and 
Borg’s22 PRE were recorded at rest and at the end of 
each test through a frequency meter - Polar® Eletro 
or Fitwatch/Finland; and a sphygmomanometer - B-
D® Germany, as well as distance covered (in meters). 
Every test was repeated twice, with 30-minute intervals 
between the fi rst test and fi rst repetition (Opasich and 
collaborators)23. The second test was always the one to 
be recorded. Tests were carried out 60 minutes apart, or 
until physiological variables returned to baseline.
Statistical software for all the analyses was Statistical 
Package for Social Sciences (S.P.S.S.). Through that 
software, chi-square tests and Fisher exact test were 
applied for the purpose of comparison of nominal 
variables. For continuous data, non-paired Student t test 
was applied. 
Variance analysis (ANOVA) was also applied with 
repeat measures to investigate statistically signifi cant 
differences between the types of exercise used in the 
study. Bonferroni procedures was used for the cases 
where the ANOVA result pointed out some statitically 
signifi cant difference.
Table  2 – Group data on infarcted patients on β-blockers (Group I): coronary angiography, ejection fraction, 
type of infarction, injured wall, and infarction time.
Coronary Angiography
 CAD* N %
  One artery 04 33.3
  2 Arteries 05 41.73
  3 arteries 02 16.7
  Lesion no obstrutive (<50%) 01 8.3
  Total 12 100.00
 Ejection Fraction (Echocardiogram) N % mrsn/dp
  ≤ 40% 01 9.09 0.35 (0.35 )
  > 40% 10 90.91 0.66 ± 0.09 (0.48 – 0.81)
  Total 11 78.57 0.63 ± 0.13 (0.35 – 0.81)
Type of infarction N %
 With supraunlevelling of ST 13 92.86
 Without supraunlevelling of ST 01 7.14
Injured wall
 Lower Wall 10 71.43
 Anterior Wall 04 28.57
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RESULTS
Results from the cardiopulmonary test did not show 
statistically signifi cant difference between the groups as 
far as VO2peak or anaerobic threshold. The only difference 
shown referred to heart rate and double product at rest, 
and exercise peak, secondary to the use of β-blocker in 
patients with previous myocardial infarction (Table 3).
Neither the 6-minute wallk tests with physiotherapist 
support (6MWTphy) nor without support (6MWTw) 
showed statistically signifi cant difference in the groups 
under study based on mean values of distance covered 
[respectively, mean distance 532.03 ± 62 m / 483.9 ± 
96.65 m; (p = 0.126), D= 467.19 ± 60 / 413.57 ± 
84; (p= 0.07)]. Difference was shown only in regard to 
heart rate and double product at rest at exercise peak, 
secondaty to the use of β-blocker in patients with previous 
myocardial infarction (p<0.001; Table 4). 
In normal elderly patients, Pearson correlation 
coeffi cient between VO2peak, obtained from CPT, and the 
distance covered in the 6MWT was shown to be strongly 
correlated, both for the test with monitoring (r = 0.791; p 
= 0.002), and in the test without monitoring (r = 0.801, 
p = 0.002) (Figures 1 and 2).
Table 3 – Cardiopulmonary test related to oxygen consumption, anaerobic threshold, heart rate  and double 
product at rest and at peak effort
Group 1
n= 14
Group 2
n = 16
P
VO2peak ml/kg/min) 19.94 ± 5.45 21.18 ± 3.51 0.4745
VO2peak ml/kg/min) 14.32 ± 3.07 15.67 ± 2.47 0.284
HR at rest (beats/min) 57.5 ± 5.76 71 ± 8.65 <0.001
HR peak  (beats/min) 104.71 ± 17.64 143.6 ± 12.8 <0.001
DP at rest(mmHg x bpm) 7430 ± 1240 8928.12 ± 1668 0.009
DPpeak (mmHg x bpm) 17537.14± 4988 25202.69± 3775 <0.001
Table 4 – Distance covered, heart rate (HR), sytolic and diastolic blood pressure, respiratory rate (RR) ( at 
rest and peak effort) and perceived exertion scale described by Borg (PES) in normal elderly with previous 
myocardial infarction, based on walk tests with and without support
Group 1
n = 14
Group 2
n = 16
TC6ac TC6s TC6ac TC6s
Distance (m) 483.9±96.65 413.57±84.36* 532.03±62 467.19±60*
HR at rest (bpm) 60±6.9 59±5.3 72.69±9.9 72.5±9.8
HRpeak (bpm) 98.92±12.9 90.79±11.9* 124.06±10 112.19±10.5*
SBP at rest (mmHg) 133.57±11.5 132.86±9.5 123.75±13 121.88±11.6
DBP at rest (mmHg) 81.43±9.49 80.71±9.8 78.75±7.2 79.38±7.7
SBPpeak (mmHg) 163.57±12.15 157.14±11.38 166.25±12.04 154.38±10.3
DBPpeak (mmHg) 91.42±11.67 87.86±8.01 83.13±7.93 81.88±6.55
RR(rpm) 32.57±3.08 27.7±3.31* 29.5±2.47 27.7±1.36*
PEf 13.93±1.2 11.79±1.05* 13.38±0.71 11.63±0.8*
(* 0.05 between 6MWTphy x 6mWTw). PEf (Borg perceived exertion scale))
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Figure 1 – Dispersion diagram correlating oxygen consumption obtained from CPT and distance covered in the  6MWT with  monitoring in “normal”  
elderly patients (r = 0.791; p = 0.002)
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Results obtained from infarcted elderly patients on β-
blockers by applying Peasron correlation coeffi cient from 
CPT, and the distance covered in the 6MWT, were shown 
to be strongly correlated, both for the test with monitoring 
(r = 0.768; p< 0.01), and the test without monitoring 
(r = 0.766, p< 0.01) (Figures 3 and 4).
When comparing the 6-minute walk tests with 
physiotherapist support (6MWTphy) and verbal stimulation 
along with patient, and without support (6MWTw), and 
the test with verbal stimulation only (6MWTw) statistically 
signifi cant difference was osbserved, with higher mean 
values of distance covered, of HR and RR, and of RPE in 
the 6MWT with physiotherapist support, both for patients 
reporting previous MI and for the elderly without clinically 
evident CHD. The 6MWTphy increased average distance 
covered by 70.33m, approximately 15% for patients 
with previous MI as compared to 6MWTw. In “normal” 
elderly patients, 6MWTphy improved performance of 
6MTWphy by increasing average distance covered by 
64.84 m, which means to say, approximately 12% (Table 
4) (Figure 5).
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Figure 2 – Dispersion diagram correlating oxygen consumption obtained from CPT and distance covered in the 6MWT without monitoring in “normal” 
elderly patients (r = 0.791; p = 0.002)
DISCUSSION
The search for alternative means to measure exercise 
capabilities has the major purpose of cutting costs and 
making easier use of those tools in extensive studies. 
Therefore, Guidelines recommendations for the ATS21 
6MWT are not designed to limit the use of alternative 
protocols in scientifi c studies. There is also the need to 
search for method adaptation for the different populations 
to be studied, for objectives to be properly addressed 
as proposed.
The groups were homogeneous in regard to age and 
gender in the present study. Females predominated in 
both groups (60% in average), similarly to data made 
available by literature, showing higher percentage of 
women in later age groups. 24,25
Based on CPT data in both groups of patients, the 
present study also found similar levels of VO2peak, and 
different HR peak exertion levels. That was due to the 
fact that infarcted elderly patients (Group 1) reported HR 
at 57.5 ± 5.76 beats/ minute at rest thanks to prolonged 
Figure 3 – Dispersion diagram correlating peak effort oxygen consumption obtained from CPT, and distance covered in the 6MWT with monitoring in 
infarcted elderly patients (r = 0.768; p<0.01)
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Figure 4 – Dispersion diagram correlating peak effort oxygen consumption obtained from CPT, and distance covered in the 6MWT without monitoring 
in infarcted elderly patients (r = 0.766; p<0.01)
use of β-blockers at such doses as to reach HR levels 
as recommended by the Brazilian and the American 
Guidelines for the treatment of CHD, thus suggesting 
that infarcted elderly that are clinically compensated by 
the use of β-blockers may report VO2peak values close to 
those of elderly patients without evident cardiopathy. 
Such result was also observed in the 6-minute walk test, 
which showed similar physical performance in the two 
groups under analysis when total distance covered was 
measured during the test. 
The present study showed significant, strong 
correlation between distances covered for both six-
minute walk test standards (6MWT), for VO2peak, 
obtained from cardiopulmonary test (CPT), and for all 
elderly individuals included in the study. Reports in the 
literature have also shown there is moderate to strong 
linear correlation between the distance covered in 6 
minutes and the VO2peak obtained from the CPT in patients 
with congestive heart failure (CHF).8,11,13,14,26,,27
Both 6MWT – with monitoring and without monitoring 
– were well tolerated by all elderly patients participating 
in the study, with no need for pauses or interruptions due 
to symptoms. The cardiopulmonary test was also well 
tolerated. It was interrupted by two elderly patients with 
previous MI, since they had presented schemic response 
only through electrocardiographic changes. Therefore, 
as electrocardiographic is not part of the 6MWT, 
recommendations from the Guidelines must be followed 
in regard to 6MWT indications and contra-indications, as 
well as interruption factors if symptoms are presented. It 
should also be carried out in a hospital environment, with 
the same emergency support as required for CPT. 21 
Although the cardiopulmonary test – whether on 
the bicycle or on the ergometric treadmill – is the most 
accurate physical performance evaluation tool, it is not 
compatible to all elderly individuals. Peeters & Mets 
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have demonstrated that 22% of all elderly patients 
with congestive heart failure were not able to fi nish 
the ergometric test due to treadmill speed and feeling 
of unstableness. All patients were able to fi nish the 
6MWT, though. 
The 6-minute walk test (6MWT) is dependent 
on motivation, learning, and diligence. Guyatt and 
collaborators have demonstrated that 6MWT with verbal 
stimulation is associated to signifi cant increase of distance 
covered. However, when 6MWT is carried out with the 
support pattern, not only the stimulus as proposed by 
Guyatt and collaborators was applied, but the presence of 
a physiotherapist was included along with patient, to give 
pace to their walk, in addition to following the protocol by 
Cavalheiro and collaborators16, which resulted in longer 
distance covered, as well as all other variables assessed 
when compared to the 6MWT with no support. 
In the present study, effort level was submaximal in all 
groups of elderly patients under analysis for the 6MWT 
with no support, as found in the literature21,13,11. However, 
the 6MWT pattern with monitoring showed that heart 
rate (HR) reached at fi nal exertion was similar to that 
obtained in maximum cardiopulmonary test (p<0.05), 
thus suggesting that 6MWT pattern stimulates higher 
cardiovascular performance.
Results from the present study have also shown that 
the 6MWT with an examiner monitoring the technique 
being used led elderly patients with previous myocardial 
infarction to reach – at test end – heart rate levels (up 
to 95% of HR from CPT) higher than those reported by 
elderly patients with no clinically evident cardiopathy (up 
to 87% of HR from CPT). That may be explained by the 
fact that in CHD individuals systolic volume is lower than 
normal, and HR is higher during exercise. That means 
to say that systolic volume decreases signifi cantly while 
under exercise requiring over 60 – 70% of VO2max, with the 
possibility of reaching HR higher than healthy individuals 
for similar effort level.28
Neither of the 6MWT patterns can directly defi ne oxygen 
consumption or accurately quantify constraint factors 
on exertion by defi ning the different pathophysiologic 
mechanisms of different systems involved. Therefore, 
both indications and contra-indications, and interruption 
factors when symptoms are present must be followed as 
set forth in the Guidelines recommendations in regard to 
6MWT. Since 6MWT cannot be risk-free, it is to be carried 
out in hospital environment with the same emergency 
support required for CPT. 
6MWT patterns are valid and reliable, and accepted 
worldwide, both for heart condition patients29 as well as 
for healthy individuals.30 However, due to sample size in 
the present study, the same cannot be said about 6MWT 
with monitoring. Our results did show, though, that the 
6MWT with monitoring would be more useful if compared 
to 6MWT with no monitoring if the purpose is to evaluate 
physical capacity, since this method would refl ect closest 
to maximal cardiovascular performance.
Additional studies are necessary to particularly 
determine the safety of 6MWT with monitoring for the 
elderly patients with previous myocardial infarction. Since 
6MWT - adopted worldwide - is submaximal, it imposes 
lower cardiovascular overburden as compared to 6MWTphy 
and is probably safer for elderly who are cardiopaths. 
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